Life Sciences Companies

BioServe Space Technologies

Boulder, United States academic

BioServe Space Technologies is a research and development organization at the University of Colorado Boulder, established in 1987 as one of NASA's original Commercial Space Centers, that specializes in developing flight-certified hardware and conducting biological and pharmaceutical research in space. Over more than 35 years, BioServe has flown over 60 research payloads aboard the Space Shuttle (in the Spacelab and SPACEHAB modules), the International Space Station, and commercial cargo vehicles including SpaceX Dragon and Northrop Grumman Cygnus. BioServe's spaceflight hardware portfolio includes cell culture systems (growing human cells, bacteria, and plant cells in microgravity), bioreactors, centrifuges that provide simulated gravity control groups alongside free-float experimental groups, fluid processing units, and imaging systems for in-situ monitoring of biological samples during flight. Research customers include major pharmaceutical companies (Merck has used BioServe hardware for protein crystallization relevant to drug design) and academic institutions studying the effects of microgravity on cell biology, cancer research, aging, and tissue engineering. BioServe provides end-to-end services: hardware design and manufacturing, NASA flight certification, experiment planning, on-orbit operations coordination with astronauts, and sample return logistics. As commercial LEO destinations (Axiom Station, Blue Origin's Orbital Reef) expand the availability of microgravity research opportunities, BioServe is positioned to extend its hardware and services expertise beyond the ISS.

Paragon Space Development

Tucson, United States commercial

Paragon Space Development Corporation is a Tucson, Arizona-based engineering company founded in 1993 by Jane Poynter and Taber MacCallum — both Biosphere 2 crew members — specializing in environmental control and life support systems (ECLSS) and thermal control systems (TCS) for human spaceflight applications ranging from near-Earth orbital habitats to deep space and lunar surface missions. Paragon's core engineering competency is the design and manufacture of closed-loop life support systems that maintain human-habitable atmospheric conditions in sealed pressurized environments: oxygen generation (via electrolysis or chemical oxygen generators), carbon dioxide removal (using lithium hydroxide canisters or regenerable 4-bed molecular sieves), humidity and temperature control, trace contaminant monitoring, and cabin pressure management. The company also develops water recovery systems that process crew condensate, urine, and wastewater through filtration and distillation into potable water — a critical system for long-duration missions where water resupply is impractical. Thermal control systems designed by Paragon manage heat rejection from spacecraft internal equipment through heat exchangers, cold plates, fluid loops (using ammonia or water as working fluid), radiators, and multi-layer insulation (MLI) blankets. For lunar surface operations, Paragon has developed regolith-facing thermal management concepts that must handle extreme temperature swings from -173°C (lunar night) to +127°C (lunar day). Paragon has contributed ECLSS hardware and engineering services to multiple programs: Bigelow Aerospace's BEAM (Bigelow Expandable Activity Module) on the ISS, NASA Commercial Crew program, Sierra Space Dream Chaser spaceplane life support design, and early-stage lunar lander habitat concepts under NASA's Artemis Commercial Lunar Payload Services (CLPS) framework. The company has also developed prototype spacesuit life support systems and portable life support system (PLSS) components. Competitors in the ECLSS space include Hamilton Sundstrand (now Collins Aerospace, which built the ISS ECLSS), Honeywell Aerospace, and NASA's own Johnson Space Center engineering teams. Paragon differentiates through its willingness to support smaller commercial customers and novel habitat architectures where legacy ECLSS vendors lack incentive to engage.

Outlier Space is developing a reusable Earth-return capsule that carries research and manufacturing payloads into microgravity for weeks to months and brings them back. The vehicle is autonomous and deliberately rocket-agnostic, so it can fly on whichever launcher is available rather than being tied to one provider, and the company is targeting better mission economics than the growing field of re-entry vehicles. The company was founded in 2024 by Jamie France, previously Rocket Lab's global director for the Electron launch vehicle, and is based in Auckland. If it flies as planned it would be New Zealand's first re-entry vehicle — a capability distinct from the launch expertise the country is already known for. Outlier raised a US$7.35 million pre-seed round led by Global From Day One, with Nova Threshold, Airtree, Icehouse Ventures, Investible, Side Stage Ventures and Brian Cartmell participating. Its target customers are in pharmaceuticals, biotechnology, advanced materials and scientific research, and a debut mission is scheduled for 2028.

Varda Space Industries

El Segundo, United States commercial

Founded in January 2021 by former SpaceX engineer Will Bruey and Founders Fund partner Delian Asparouhov, Varda Space Industries is pioneering in-space pharmaceutical manufacturing using microgravity to create superior drug formulations. The company designs spacecraft that process small molecule pharmaceuticals in microgravity where suppressed convection and sedimentation produce more uniform crystals, improving drug shelf-life, bioavailability, and patient experience. In February 2024, Varda made history as only the third company ever to return materials from orbit, successfully bringing back ritonavir HIV medication crystals from their W-1 mission after navigating complex regulatory approvals. With $329 million raised through Series C funding, the El Segundo-based company has flown a series of W-class reentry capsules, with missions through W-6 listed on its own platform page, demonstrating that materials can be processed in orbit and returned to Earth commercially.

AstraZeneca Space Research refers to the ISS-based biologics and cell-therapy research run by AstraZeneca, the pharmaceutical group formed in 1999 from the merger of Sweden's Astra AB and Britain's Zeneca Group, headquartered in Cambridge, UK, listed on the London Stock Exchange, Nasdaq Stockholm and NYSE as AZN, and employing about 89,900 people as of 2025. The company has run several distinct investigations aboard the International Space Station National Laboratory: nanoparticle formation for cancer vaccines, examining how microgravity affects the development of nanoparticles used in therapeutic cancer vaccines; monoclonal antibody production and stability, since these biologic molecules are used to treat cancer and autoimmune disease; and regenerative-medicine work on cell therapies targeting leukemia, breast cancer and glioblastoma. According to the ISS National Lab, AstraZeneca's nanoparticle cancer-vaccine research launched on SpaceX's CRS-17 cargo mission in April 2019, and its monoclonal-antibody stability study launched on SpaceX's CRS-18 mission in July 2019. The company is named by the ISS National Lab alongside Sanofi Pasteur, Merck, Bristol Myers Squibb, Eli Lilly and GlaxoSmithKline as one of several major pharmaceutical companies leveraging microgravity to improve biopharmaceutical manufacturing and drug development. As with the other large drugmakers running similar programs, AstraZeneca's space-based research is one research line within a much larger global pharmaceutical business rather than a separately incorporated company.

Bristol Myers Squibb Space Research refers to the ISS-based drug-development program of Bristol Myers Squibb (BMS), the pharmaceutical group founded in 1887, registered in Princeton, New Jersey, listed on the NYSE as BMY, and employing about 32,500 people as of 2025. BMS studies protein crystallization and alternative drug-delivery methods aboard the International Space Station National Laboratory, with a specific goal of finding ways to replace scheduled medication infusions with quick injections for patients. The company's main ISS research vehicle has been Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) facility, a commercial service provider platform used to examine small-molecule compound crystallization in microgravity. BMS payloads have flown on multiple SpaceX Commercial Resupply Services missions to the station, including CRS-27 in March 2023, continuation supplies on CRS-28 in May 2023, and further work on CRS-31 in November 2024. The company has also run tissue-chip investigations aboard the ISS to gather drug-development insights that are difficult to obtain in terrestrial cell culture. BMS is represented on the ISS National Laboratory's Applied Research and Development Subcommittee, with the company's participation attributed to representatives including Robert Garmise. As with other large drugmakers using the station -- Sanofi, Merck, Eli Lilly, GlaxoSmithKline and AstraZeneca among them -- this space research is a specific, ongoing R&D program rather than a separately incorporated business.

GlaxoSmithKline Space Research refers to the ISS-based biologics research run by GSK plc, the UK pharmaceutical group formed in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham, headquartered in London, listed on the London Stock Exchange as GSK, and employing roughly 65,000 people. GSK studies the stability and aggregation behavior of therapeutic monoclonal antibodies in the microgravity environment of the International Space Station National Laboratory, seeking to better understand the mechanics of protein aggregate formation that can limit a biologic drug's shelf life or effectiveness. The program's co-principal investigators are Dr. Deidre Dalmas Wilk and Dr. Matthew Henry; Dalmas Wilk also sits on the ISS National Lab's Science Subcommittee User Advisory Committee, giving GSK a direct role in shaping station research priorities beyond its own experiments. According to the ISS National Lab, GSK's monoclonal-antibody stability investigations were manifested on the Northrop Grumman CRS-14 cargo mission in September 2020 and the Northrop Grumman CRS-16 mission in August 2021. GSK is named by the ISS National Lab alongside Merck, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Sanofi as one of several major pharmaceutical companies that have moved biologics-stability and drug-development research onto the space station. As with those peers, this is a specific, ongoing research program inside a much larger global pharmaceutical business rather than a standalone company.

Novartis Space Research refers to the ISS-based rodent-physiology program run by the Novartis Institutes of Biomedical Research, the R&D arm of Novartis, the Swiss pharmaceutical group formed in 1996 from the merger of Ciba-Geigy and Sandoz, headquartered in Basel, listed on the SIX Swiss Exchange as NOVN and on the NYSE as NVS (ADS), and employing roughly 75,900 people as of 2024. Novartis's research has focused on muscle wasting (sarcopenia) in microgravity, including work on an implantable device designed to safely administer a muscle-wasting drug over a long period, developed with partners Houston Methodist Research Institute and NanoMedical Systems alongside NASA. The program flew mice to the International Space Station on NASA's Rodent Research-1 (RR-1) mission, which carried five wild-type mice, launched aboard a SpaceX Dragon capsule in September 2014. It continued with Rodent Research-2 (RR-2), led by Dr. Samuel Cadena, which monitored the effects of microgravity on rodent muscle and bone. Results from the first rodent-research mission were published in June 2019, with related publications appearing from 2014 through 2021. The ISS National Lab highlights Novartis as one of the earlier pharmaceutical users of the station's Rodent Research Facility for translational muscle and bone research, a line of work distinct from the protein-crystallization and antibody-stability studies run by pharmaceutical peers such as Merck, Eli Lilly, Sanofi, Bristol Myers Squibb, GlaxoSmithKline and AstraZeneca. It remains a specific research program within Novartis's much larger global pharmaceutical business rather than a separate company.

Sanofi Space Research refers to the ISS-based vaccine research run by Sanofi Pasteur, the vaccines division of French pharmaceutical group Sanofi (founded 1973, headquartered in Paris, listed on Euronext Paris as SAN and Nasdaq as SNY, with roughly 83,000 employees). Sanofi uses BioServe Space Technologies as its implementation partner to fly experiments to the International Space Station National Laboratory studying how the microgravity environment affects vaccine performance. Its documented research includes an 'MDCK Influenza Virus Infection' investigation examining how influenza virus behaves in microgravity, with the goal of informing more effective vaccines, particularly for older adults whose immune response to flu vaccination is typically weaker. According to the ISS National Lab, the project has produced what it described in 2026 as 'unexpected' findings that could help improve vaccine design. Sanofi's ISS research activity is documented from at least 2019 through 2026, and its payloads have flown on ISS cargo resupply missions, including a presence referenced on the SpaceX CRS-21 mission manifest in November 2020. The ISS National Lab lists Sanofi alongside several other large pharmaceutical companies -- including Merck, Eli Lilly, Bristol Myers Squibb, GlaxoSmithKline and AstraZeneca -- as part of a broader wave of drugmakers using the station to study protein behavior, vaccine formulation and drug stability under conditions that cannot be replicated on Earth. As with those peers, the space research is a minor, specific R&D program within a far larger global pharmaceutical business rather than a separate operating company.